According to a media announcement shared with MHW moments ago, digital health technology leader WellDoc confirmed today it has entered a commercial partnership agreement with LifeScan Inc., one of the Johnson & Johnson Diabetes Care Companies (JJDCC) and a world leader in blood glucose monitoring, to deliver across the United States a “best-in-class digital health solution for Type 2 diabetes.”
The companies will integrate WellDoc’s BlueStar diabetes management platform and mobile application, which is the first digital therapeutic approved by the U.S. Food and Drug Administration for adults who live with Type 2 diabetes, with LifeScan’s OneTouch Verio Flex blood glucose monitoring system with built-in Bluetooth Smart Technology and the OneTouch Reveal digital system.
The combined offering will seek to create a comprehensive, data-driven and payer-reimbursed program for Type 2 diabetes management.
“We’ve made considerable progress in our important relationship with LifeScan, Inc., which began earlier this year via a development agreement and a Johnson & Johnson Innovation – JJDC, Inc. investment in WellDoc. Together, WellDoc and LifeScan will provide those living with Type 2 diabetes a best-in-class diabetes management solution with robust data analytics powered by BlueStar’s patented clinical and behavioral engine,” said Kevin McRaith, CEO of WellDoc. “We will facilitate national adoption of this innovative first-in-class digital health solution. Our goal is to help make a difference in the lives of millions of Americans living with this chronic disease while bringing the U.S. healthcare system cost-savings opportunities.”